Structure of the Predominant Protein Arginine Methyltransferase PRMT1 and Analysis of Its Binding to Substrate Peptides

Xing Zhang, Emory University
Xiaodong Cheng, Emory University

Journal Title: Structure
Volume: Volume 11, Number 5
Publisher: Elsevier (Cell Press) | 2003-05, Pages 509-520
Type of Work: Article | Post-print: After Peer Review
Publisher DOI: 10.1016/S0969-2126(03)00071-6
Permanent URL: http://pid.emory.edu/ark:/25593/g2d6p

Final published version: http://dx.doi.org/10.1016/S0969-2126(03)00071-6

Copyright information:
© 2003 Cell Press. Published by Elsevier Inc.
This is an Open Access work distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Accessed December 7, 2018 6:13 AM EST
Structure of the Predominant Protein Arginine Methyltransferase PRMT1 and Analysis of Its Binding to Substrate Peptides

Xing Zhang and Xiaodong Cheng*
Department of Biochemistry
Emory University School of Medicine
1510 Clifton Road
Atlanta, Georgia 30322

Summary

PRMT1 is the predominant type I protein arginine methyltransferase in mammals and highly conserved among all eukaryotes. It is essential for early postimplantation development in mouse. Here we describe the crystal structure of rat PRMT1 in complex with the reaction product AdoHcy and a 19 residue substrate peptide containing three arginines. The results reveal a two-domain structure—an AdoMet binding domain and a barrel-like domain—with the active site pocket located between the two domains. Mutagenesis studies confirmed that two active site glutamates are essential for enzymatic activity, and that dimerization of PRMT1 is essential for AdoMet binding. Three peptide binding channels are identified: two are between the two domains, and the third is on the surface perpendicular to the strands forming the β barrel.

Introduction

Protein arginine methylation is a common posttranslational modification in eukaryotes. The major type of protein arginine (R) methyltransferase (PRMT), type I, transfers the methyl group from S-adenosyl-L-methionine (AdoMet) to the guanidino group of arginines in protein substrates, resulting in monomethylarginine and asymmetric dimethylarginine in substrate proteins [1]. The best known substrates for type I PRMT are RNA binding proteins involved in various aspects of RNA processing and/or transport, such as hnRNPs, fibrillarin, nucleolin [2], and poly(A) binding protein II [3]. More recently, a growing number of other proteins have been found to be substrates of PRMT1, including high molecular weight fibroblast growth factor 2 (HMW FGF-2, a nuclear growth factor [4]), interleukin enhancer binding factor 3 (ILF3) [5], STAT1, a transcription factor activated by extracellular signals [6], and histone H4 [7, 8]. Most PRMT1 substrates contain glycine- and arginine-rich (GAR) sequences that include multiple arginines in RGG or RXR contexts [2–4]. However, increasing numbers of substrates lacking GAR domain are being discovered [9], including STAT1 and histone H4, which contain no other arginines near the methylation target.

PRMT genes are present in eukaryotes from fungi to plants and animals. Though Saccharomyces cerevisiae has only one PRMT homolog [10, 11], multiple genes have been found in plants and animals. For example, six very similar paralogous mammalian PRMT genes have been reported so far: PRMT1, PRMT2, PRMT3, CARM1/PRMT4 [12–17], JBP1/PRMT5 [18, 19], and PRMT6 [20]. At least eight PRMTs are present in the completed Drosophila melanogaster genome (X.Z., unpublished observation). The presence of a large number of PRMTs may signify the diverse roles PRMTs can play.

How does arginine methylation affect protein function? There is some evidence that arginine methylation can affect a protein’s affinity for RNA [21]. However, at least in the case of Hrp1p binding to its specific, high-affinity RNA target, arginine methylation does not seem to affect the strength of nucleic acid binding [22, 23]. More recent evidence suggests that arginine methylation affects the interaction of the substrate proteins with other proteins [6, 24, 25] as well as their subcellular localization in yeast and mammalian cells [26–29]. Arginine methylation has been implicated in receptor-mediated signaling [5, 12, 17, 30], in some cases through methylation of a transcription factor or cofactor [6, 25]. Histone arginine methylation is a component of the “histone code” that directs a variety of processes involving chromatin [31, 32]. For example, methylation of Arg3 of histone H4 by PRMT1 facilitates H4 acetylation and enhances transcription activation by nuclear hormone receptors in a synergistic fashion to CARM1 [8, 25, 33, 34].

PRMT1 is the predominant type I PRMT in mammalian cells, accounting for 85% of cellular PRMT activity [35, 36]. It is essential for early postimplantation development, as shown by the embryonic lethality of mouse PRMT1−/− mutants [36]. PRMT1 is expressed at detectable levels in all tissues examined [15–17, 36] (the highest is in developing neural structure in embryos [36]), and PRMT1 has been implicated in neuronal differentiation [37]. Besides the numerous substrates that interact with PRMT1, other proteins also bind to PRMT1. For example, antiproliferative protein interferon receptor IFNAR-1 [38] and BTG/TOB proteins [17, 39] bind PRMT1 and modulate its activity, and p160 nuclear hormone coactivators bind PRMT1 and recruit it to its substrate such as histone H4 [33].

PRMT1 gene is found in all eukaryotes tested and is highly conserved (Figure 1A). The sequence identity is over 90% among mammals, zebrafish, and Xenopus, and about 50% even between human and S. cerevisiae. There appears to be another gene closely related to PRMT1 genes both in A. thaliana and in human (PRMT1L3, XP_077339, on chromosome 12p13), which in each case shares 80% amino acid identity with PRMT1. Except for the N terminus, the two genes have identical genomic structure: each pair has eight introns inserted at identical positions, and the locations of seven of those introns are also shared between human and A. thaliana. No function for this PRMT1-like gene has been reported. Like S. cerevisiae, C. elegans and S. pombe have only one copy of PRMT1 and share some of the

Key words: protein arginine methylation; AdoMet-dependent methylation; glycine- and arginine-rich (GAR) sequence; RGG repeats; PRMT dimerization and oligomerization

*Correspondence: xcheng@emory.edu
Figure 1. Members of the PRMT1 Family

(A) Structure-based sequence alignment of rat PRMT1, PRMT3 [43], and yeast RMT1 [44]. Letters (A–Z) for helices and numbers (1–15) for strands indicate the secondary structure elements of rat PRMT1 or PRMT3; residue numbering is shown above or below the sequences. The color coding is red for the N terminus including helix αY (residues 41–51), green for the AdoMet binding domain (residues 52–176), yellow for the barrel structure (residues 177–187 and 217–352), and blue for the dimerization arm (residues 188–216). For rat PRMT1, the amino acids highlighted (white against black) are invariant among PRMT1s from various organisms: rat PRMT1 (GenBank accession number NP_077339), human PRMT1-v2 (modified from CAA71764), PRMT1-like (also called HMT1L3, XP_006990), C. elegans PRMT1 (CAB54335), D. melanogaster PRMT1 (AAF54556), A. thaliana PRMT1 (CAB79709), D. melanogaster PRMT1 (AAF54556), A. thaliana PRMT1-like (AAC62148), S. pombe PRMT1 (CABS3498), and S. cerevisiae RMT1 (585608). The Xenopus and zebrafish PRMT1 sequences were assembled from ESTs with sequences highly similar to that of rat PRMT1. The N-terminal sequences shown with a strikethrough are not observed in the crystal structures, presumably due to being highly disordered in the crystals. The asterisks above the sequence indicate residues important for cofactor binding (see Figure 4A) and/or catalysis (see Figure 7A).

(B) N-terminal splicing variants of human PRMT1. The N terminus is the least conserved region among PRMT1s (Figure 1A). Three splicing variants (v1–v3) at the N terminus have been documented in human [15], producing mRNAs coding proteins between 353–371 amino acids long slightly different at their N termini [15, 36]. Variants v1 and v2 are also found in mouse, and v1 is found in rat. The two splicing variants of mouse are both expressed in all the tissues examined [36]. It has been reported that the 353 amino acid v1 and 371 amino acid v2 mouse PRMT1 have different substrate specificity [40]. By comparing available human PRMT1 ESTs with the genomic sequence (AC011495.1), at least three additional N-terminal splicing variants (v4–v6) can be identified (Figure 1B). In Xenopus, at least two versions corresponding to the mammalian v1 and v2 can also be found in the available EST sequences (BE025764 for v1; BE025764 for v2).

The vast majority of human and mouse ESTs represent splicing version 1, which encodes a protein of 353 amino acids. The wild-type PRMT1 we used is the rat PRMT1v1, which is identical to the mouse protein and differs from the human enzyme at only one position (H161 is Y in human). The previously reported human version 1 sequences (AAEF62895 and CAA71765) lack the first ten amino acids of the rat sequence. However, close examination of the genomic sequence of human
Figure 2. Activity of PRMT1 Proteins
(A) Reactions (20 μl) contained 4 or 8 μM of purified hnRNP A1 (130 or 260 μg/ml), 40 μM [methyl-3H]AdoMet (0.5 Ci), and the indicated amount of PRMT1 in 100 mM Tris (pH 8.0), 200 mM NaCl, 2 mM EDTA, and 1 mM dithiothreitol. After incubating at 37°C for 15 min, the samples were analyzed by SDS-PAGE. The upper panel shows the Coomassie-stained gel of total PRMT1 and hnRNP A1, while the lower panel shows the image resulting from fluorography. Various amounts of wild-type PRMT1 (lanes 3–5, 11–15, and 21–23) were used so that the relative activity of mutant PRMTs could be estimated.

(B) Methylation of peptides R3 or R1 (RGG) and competition by hnRNP A1. Reaction conditions are identical to Figure 2A and include 10 μg/ml of PRMT1, 5 μM of hnRNP A1 and/or various amounts of peptides as indicated.

(C) Time course of AdoMet crosslinking of wild-type PRMT1 and ARM mutant.

(D) AdoMet crosslinking of various PRMTs and mutants. The samples were treated with UV for 1 hr. Controls were used: yRMT1 (yeast RMT1), PRMT3 (full-length rat PRMT3), PRMT3Δ200 (rat PRMT3 conserved core), and HhaI (DNA cytosine methyltransferase).

PRMT1 (AC011495.1) and of many ESTs (e.g., BE882188) suggests the presence of an additional exon that would add the same ten N-terminal amino acids to the human sequence. Here we present the structures of PRMT1-AdoHcy and its complex with peptide substrates, solved by molecular replacement using PRMT3 core structure [43]. These structures reveal active site residues, confirmed by mutagenesis studies, and indicate the locations of peptide binding channels. The oligomerization behavior of PRMT1, in solution and in crystal, is also discussed in comparison with the yeast RMT1 structure [44].

Results and Discussion

Overall Structure of PRMT1
We expressed the rat PRMT1v1 (353 amino acids) as a fusion protein containing a short N-terminal His tag (MGHHHHHH). The enzyme was very active using either hnRNP A1 (Figure 2A) or a 19 residue peptide (R3; Figure 2B) as substrate. Limited proteolysis using V8 or elastase resulted in very stable fragments lacking the first 10 or 13 residues, respectively (data not shown). His tag fusion proteins corresponding to these stable fragments (named M11 or S14) have similar enzymatic activity (Figure 2A, lanes 1–7) and form similar sizes of oligomers as the full length (Table 1). The deletions crystallized more readily than the full-length protein, and structures containing these two deletions or a full-length PRMT1 containing an E153Q mutation at the active site (see below) were determined (Table 2). All crystals contained the methylation product AdoHcy, and S14 and full-length E153Q also contained substrate peptide R3 (19 amino acids) or R1 (10 amino acids), respectively. They belong to the primitive tetragonal space group P4(2)2(1).
crystal (Table 2). In all three structures only the residues after amino acid 40 were observed, suggesting a disordered amino terminus. There are few significant structural differences among the three protein structures, and we describe primarily the tertiary structure of S14-AdoHcy-R3 unless otherwise indicated.

The overall monomeric structure of PRMT1 can be divided into four parts (Figure 3A): N-terminal (red), AdoMet binding (green), β barrel (yellow), and dimerization arm (light blue). The AdoMet binding domain has the consensus fold conserved in other AdoMet-dependent methyltransferases [41, 42], whereas the β barrel domain is unique to the PRMT family [43]. Besides the N terminus (see below), the only size differences between PRMT1 and PRMT3 are in the β barrel domain—a single-residue deletion in the loop between strands β10 and β11 and an 8 residue insertion between strands β14 and β15 (Figure 3B). The additional 8 residues near the C terminus result in longer strands β14 and β15, while maintaining the exact position of the carboxyl group COO- of the C-terminal residue next to the active site (Figure 3B). Interestingly, the position of the carboxyl terminus is also the same in the yeast RMT1 structure [44], which has an even larger insertion between strands β14 and β15 (see Figure 1A). This raises the possibility that the negatively charged C-terminal carboxyl group has an important role for binding positively charged substrate and/or for catalysis.

**Cofactor Binding**

The cofactor product, AdoHcy, which was present during crystal growth (see Experimental Procedures), is observed in a deep pocket on the carboxyl ends of the parallel strands β1–β5 (Figure 3A), surrounded by residues that are highly conserved in the PRMT family (Figure 4A). The interactions can be grouped according to the three moieties of AdoHcy: (1) the Gly-rich loop (G78 and G80) after strand β1 makes the backbone van der Waals contacts to the AdoHcy homocysteine and adenosine ribose moieties; (2) the acidic residue at the carboxyl end of strand β2 (E100) forms bifurcated hydrogen bonds with the ribose hydroxyl oxygens; and (3) the acidic residue from the loop after strand β3 (E129) hydrogen bonds with the amino group of adenine. These three interactions are conserved among many structurally characterized consensus AdoMet-dependent methyltransferases, and define the structural context of the AdoMet/AdoHcy binding site [41, 42]. Unique interactions for PRMT1 (and other members of the PRMT family) include H45 of helix αY (hydrogen bonding with one of

Table 1. Summary of Characterization of PRMT1 Mutants

<table>
<thead>
<tr>
<th>Plasmid</th>
<th>Protein</th>
<th>Expression</th>
<th>Solubility</th>
<th>GF Size (kDa)</th>
<th>DLS size (kDa)</th>
<th>Activity (hnRNP A1)</th>
</tr>
</thead>
<tbody>
<tr>
<td>pXC168</td>
<td>WT</td>
<td>++</td>
<td>+</td>
<td>320</td>
<td>780</td>
<td>+ AdoHcy 100%</td>
</tr>
<tr>
<td>pXC246</td>
<td>WT (no tag)</td>
<td>++</td>
<td>++</td>
<td>400</td>
<td>Not done</td>
<td>+ AdoHcy + R3</td>
</tr>
<tr>
<td>pXC247</td>
<td>M11 (no tag)</td>
<td>++</td>
<td>++</td>
<td>250</td>
<td>360</td>
<td>+ AdoHcy ~100%</td>
</tr>
<tr>
<td>pXC248</td>
<td>M11</td>
<td>++</td>
<td>+</td>
<td>250</td>
<td>300</td>
<td>~100%</td>
</tr>
<tr>
<td>pXC249</td>
<td>S14</td>
<td>++</td>
<td>+</td>
<td>250</td>
<td>&gt;2 K</td>
<td>400 ~100%</td>
</tr>
<tr>
<td>pXC250</td>
<td>S38</td>
<td>+</td>
<td>+</td>
<td>250</td>
<td>240</td>
<td>Not detected</td>
</tr>
<tr>
<td>pXC256</td>
<td>L49</td>
<td>++</td>
<td>+</td>
<td>250</td>
<td>370</td>
<td>Not detected</td>
</tr>
<tr>
<td>pXC252</td>
<td>E153Q</td>
<td>+</td>
<td>+</td>
<td>250</td>
<td>370</td>
<td>Not detected</td>
</tr>
<tr>
<td>pXC258</td>
<td>E153D</td>
<td>+</td>
<td>+</td>
<td>300</td>
<td>450–3 K</td>
<td>320–400 ~0.03%</td>
</tr>
<tr>
<td>pXC255</td>
<td>E144Q</td>
<td>+</td>
<td>+</td>
<td>Void</td>
<td>&gt;2 K</td>
<td>&gt;2 K ~0.03%</td>
</tr>
<tr>
<td>pXC257</td>
<td>E144D</td>
<td>+</td>
<td>+</td>
<td>600</td>
<td>970</td>
<td>620 10%</td>
</tr>
<tr>
<td>pXC335</td>
<td>M11 C254S</td>
<td>++</td>
<td>+</td>
<td>250</td>
<td>Not done</td>
<td>375 ~100%</td>
</tr>
<tr>
<td>pXC336</td>
<td>M11 ΔARM</td>
<td>++</td>
<td>+/-</td>
<td>37</td>
<td>Not done</td>
<td>Not done Not detected</td>
</tr>
</tbody>
</table>

The size of the oligomer is affected by the presence of cofactor AdoMet or product AdoHcy. In the absence of added AdoMet or AdoHcy, the protein eluted from gel filtration (GF) column S300HR (Pharmacia) as an asymmetrical peak with a long trailing tail, with the peak corresponding to a protein of about 500 kDa. When the protein was preincubated with AdoHcy, it eluted as a 320 kDa protein with a symmetrical elution profile. This is very similar to the endogenous PRMT1 in rat or HeLa cell extract, which eluted as a 330 kDa complex [8, 16]. Dynamic light scattering (DLS) measurement suggested that the size of PRMT1 oligomer is also influenced by temperature and protein concentration. The oligomer size has a lower limit of about 300 kDa but can go beyond 1000 kDa at lower temperature and higher protein concentration.

Table 2. Summary of X-Ray Data Collection and Model Refinement of PRMT1

<table>
<thead>
<tr>
<th>Plasmid</th>
<th>pXC248</th>
<th>pXC249</th>
<th>pXC252</th>
</tr>
</thead>
<tbody>
<tr>
<td>Protein complex</td>
<td>M11 + AdoHcy</td>
<td>S14 + AdoHcy + R3</td>
<td>E153O + AdoHcy + R1</td>
</tr>
<tr>
<td>Cell dimensions (Å)</td>
<td>88.3 × 88.3 × 145.1</td>
<td>86.5 × 86.5 × 142.4</td>
<td>87.8 × 87.8 × 144.6</td>
</tr>
<tr>
<td>Resolution limit (Å)</td>
<td>2.50</td>
<td>2.35</td>
<td>2.64</td>
</tr>
<tr>
<td>Completeness (%)</td>
<td>98.6</td>
<td>96.3</td>
<td>99.8</td>
</tr>
<tr>
<td>Rmerge</td>
<td>0.100</td>
<td>0.037</td>
<td>0.084</td>
</tr>
<tr>
<td>&lt;(I&gt;/&lt;I&gt;)</td>
<td>9.2</td>
<td>20.7</td>
<td>20.8</td>
</tr>
<tr>
<td>Observed reflections</td>
<td>102,483</td>
<td>77,491</td>
<td>116,340</td>
</tr>
<tr>
<td>Unique reflections</td>
<td>20,200</td>
<td>22,428</td>
<td>17,213</td>
</tr>
<tr>
<td>Rmerge</td>
<td>0.199</td>
<td>0.195</td>
<td>0.186</td>
</tr>
<tr>
<td>Rfree</td>
<td>0.263</td>
<td>0.254</td>
<td>0.249</td>
</tr>
<tr>
<td>PDB</td>
<td>1ORI</td>
<td>1OR8</td>
<td>1ORH</td>
</tr>
</tbody>
</table>
Figure 3. Structure of PRMT1

(A) Two views (top and bottom panels) of monomer structure. The N-terminal helix αY is shown in red, and the AdoMet binding domain in green. The bound AdoHcy is shown in a stick model with the sulfur atom (where the transferable methyl group would be attached in AdoMet) shown in yellow. The β barrel structure is shown in yellow, and the dimerization arm (which is inserted into the β barrel) is in light blue (see Figure 1A). The bound arginine (blue) in the S14-AdoHcy-R3 ternary complex defines the active site, located between the AdoMet binding domain (green) and the β barrel (yellow).

(B) Superposition of PRMT1 (residues 41–353, colored according to Figure 1A) and PRMT3 core (residues 208–528, in gray). Besides deletion or insertion (located in loops between β10 and β11 and between β14 and β15), the two structures can be superimposed with less than 1 Å of root-mean-square deviation between them.
crosslinking experiments (Figure 2C, and Figure 2D, lane 11). A similar mutant of yeast RMT1 that replaces the arm with alanines also resulted in the loss of dimer formation and methylation activity [44]. In the crystal structure, the dimer interface is formed between the arm and the outer surface of the AdoMet binding site (Figure 5C). It is conceivable that the dimer interaction is required to engage the residues on the other side of the structural elements (αY-loop-αZ and β1-loop-αA) to interact with AdoMet properly.

Another potential function of the conserved PRMT dimer might be to allow processive production of the final methylation product, asymmetric dimethylarginine. PRMT substrates isolated in vivo are usually completely or nearly completely dimethylated [3, 4, 45–47]. It has been shown in vitro that PRMT6 forms dimethylarginine in a processive manner [20]. It is conceivable that a ring-like dimer could allow the product of the first methylation reaction, monomethylarginine, to enter the active site of the second molecule of the dimer, without releasing the substrate from the ring or replenishing the methyl donor.

In addition to the dimer interaction, we also observed a disulfide bond between C254 from strand β9 of two crystallographically related molecules. This interaction caused PRMT1 dimers to form an extended polymer in the crystal lattice (Figure 5A). The recombinant PRMT1 protein existed as an oligomer as judged by gel filtration chromatography and dynamic light scattering (Table 1). However, yeast RMT1 exists mainly as a dimer in solu-
Figure 5. Dimer Formation of PRMT1
(A) Two ring-like dimers (related by a crystallographic 2-fold) connected by a surface C254 via a disulfide bond are shown with a difference electron density map contoured at 5.5σ. The dimer is formed through the arm (blue) and the outer surface of AdoMet binding domain (green), as indicated. The AdoHcy (gray) is in a stick model.
(B) Two opposite GRASP surfaces of PRMT1 dimer. The surface is colored red for negative, blue for positive, and white for neutral.
(C) Two opposite GRASP surfaces of PRMT1 monomer. Dimerization is mediated through hydrophobic patches of the arm and the outer surface of AdoMet binding domain, as indicated.

Substrate Binding Surface
The peptides that contain one or three copies of the consensus RGG repeat sequence (R1 or R3, respectively) were cocrystallized with PRMT1. As shown in Figure 2B, the R3 peptide is a very good substrate for PRMT1 (lanes 7–11) and competes with a protein substrate hnRNP A1 effectively (lanes 1–6). In contrast, the R1 peptide competes poorly with hnRNP A1 (lanes 12–17), and was barely methylated under similar conditions (data not shown).

The substrate binding surface of PRMT1 is expected to be acidic, because most substrates for PRMT1 contain multiple arginines. As shown in the surface charge distribution of PRMT1 dimer (Figure 5B), acidic residues are enriched on the inner surface of the dimer ring and the outer surface of the β barrel. The structure of the ternary S14-AdoHcy-R3 complex included electron densities revealing the location of bound peptide ligands (Figure 6). However, the densities were broken into three separate peptide fragment binding sites (P1, P2, and P3), and, except for the arginine in the active site, the side chain densities were not sufficiently resolved to allow clear identification of the amino acids. In comparison, no density was observed in any of the three P sites in the structure of M11-AdoHcy without peptide.

The three disconnected densities probably represent a mixture of binding modes of R3 peptide, which contains three potential methylation targets at positions 3, 9, and 15. Sites P1 and P2 correspond to the acidic grooves in the interface between the two domains (green and yellow in Figure 6B), P1 is along the edge of helices αY (red) and αZ (green) and next to strand β11 and the THW loop (Figure 6B). P2 is flanked by helix αD (green) and the short 310 helix αI as well as the loop between β13 and β14 (yellow). If the central Arg9 were the target,
Figure 6. Structure of Ternary Complex of S14-AdoHcy-R3 Peptide (Sequence Shown at the Top)

(A) Solvent-accessible molecular surface with bound AdoHcy and Arg shown as stick models and indicated by the arrows. In the absence of helix $\alpha X$ (see Figure 3B), which is disordered in the PRMT1 crystals, AdoHcy is exposed and readily visible. The three discontinuous peptide binding sites P1, P2, and P3 are shown as green tubes.

(B) Ribbon representation of (A) with the three peptide binding sites shown as annealed omit electron densities (black) contoured at 5.0.$\sigma$. Some of the structural elements flanking sites P2 and P3 are labeled.

(C) A 90° rotation of (B) showing that the binding sites P1 and P2 can be connected so that the middle Arg9 of peptide R3 is bound at the active site.

(D) Two side views of (A) showing the three peptide binding sites as well as other acidic grooves parallel to P3 (indicated by the arrows). The acidic residues flanking these grooves are labeled. In the left panel, it can be seen that connecting P2 and P3 would place the terminal arginine (Arg3 or Arg15) at one end of P2 in the active site.

bound in the active site, connecting peptide binding sites P1 and P2 would cover the active site and the entire length of the peptide (Figure 6C). The densities immediately around the active site arginine are not observed, and the gaps account for the two glycines flanking the arginine. Due to the ambiguous nature of the density, the peptide can be fitted equally well in either linear orientation. The acidic grooves containing P1 and P2 are almost parallel to the N-terminal helices $\alpha Y$ (Figure 6B) and $\alpha X$ (if present analogously to the PRMT3 structure), respectively. It is conceivable that the rest of the N-terminal sequences differing among PRMT1 splicing variants could also be in the vicinity to contact the protein substrate occupying the P2 binding groove, consistent with the observation that PRMT1 splicing variants have different substrate specificity [40].

Site P3 corresponds to one of the grooves (Figure 6D) perpendicular to the sheet formed by $\beta$ strands 9, 13, 14, and 15 (see Figure 3A). When the end arginine (either Arg3 or Arg15) is bound in the active site, connection
Figure 7. Active Sites of PRMT1 and PRMT3

(A) PRMT1 active site with bound Arg in stereo. The annealed omit electron density map, contoured at 5.0σ of the arginine, is shown as an insert.

(B) Superimposition of PRMT1 and PRMT3 (PDB ID code 1F3J) active sites in stereo. Only the PRMT3 residues are labeled. The arrow indicates transfer of the methyl group (attached to AdoHcy) to the bound Arg.

(C) pH dependence of PRMT1 and PRMT3 activities. Reactions (20 μl) contained 5 μM of purified hnRNP A1 or 100 μM of R3 peptide, 10 μg/ml of PRMT1 or 50 μg/ml of PRMT3, 200 mM NaCl, 2 mM EDTA, and 1 mM dithiothreitol. The buffers used were sodium acetate (pH 4 and 5), MES (pH 6.0, 6.3, 6.5, and 6.8), HEPES (pH 7.0 and 7.5), Tris (pH 8.0 and 8.5), and glycine (pH 9.0, 9.5, and 10.0). After incubating at 37°C for 15 min, 2.5 μl of 100 mg/ml BSA was added, followed by 0.5 ml of 20% TCA. The samples were filtered and washed three times with 20% TCA through a GF/F filter (Millipore), dried, and subjected to liquid scintillation counting.

of peptide binding sites P2 and P3 would account for the length of the whole peptide (Figure 6D). Additional acidic grooves running parallel to site P3 can be identified. These grooves could form additional binding sites for protein substrate with more RGG repeats.

In the case of R1 peptide, which is a poor substrate, no density was observed in the active site or the peptide binding sites P1 and P2 in the structure of the E153Q-AdoHcy-R1 ternary complex. However, we did observe residual, broken density in the peptide binding site P3 (not shown), which is away from the active site. Perhaps the preferential binding to this nonproductive site is the
cause for R1 peptide being a poor substrate. Alternatively, E153Q mutation could prevent stable binding of the peptide in the active site.

Active Site
The target arginine is situated in a deep pocket between the AdoMet binding domain and the β barrel domain (Figure 6A). The residues that make up the active site are conserved across the PRMT family, and form a hairpin between strand β4 and helix αD. This is called the “double-E loop” because it contains two invariant glutamates (E144 and E153; Figure 1A). The hydrophobic methylene groups of the target arginine lie parallel to the plane of the Y148 aromatic ring, while the side chain of E144 and the main chain carbonyl oxygen of E153 hydrogen bond the guanidino group (Figure 7A).

Surprisingly, the side chain of E153 points away from, rather than toward, the bound guanidino group in the active site. We noted that all three forms of PRMT1 were crystalized at low pH (~4.7); under this condition PRMT1 is inactive (Figure 7C), perhaps due to protonation of one or both Glu side chains. Consistent with the effects of protonation, E153Q mutation abolished methylation activity (Figure 2A, lane 16; Table 1), whereas the E153D mutation reduced the activity to about 0.03% (Figure 2A, lane 17; Table 1). Both E153 mutants (D and Q) oligomerized to about the same size as the wild-type (Table 1), indicating that the mutations did not affect the overall structural integrity of the protein. On the other hand, regarding the second glutamate in the double-E loop, both E144 mutants (particularly E144Q) are more aggregated (Table 1), suggesting that the mutations may cause some structural perturbation by interrupting E144-R54 interaction (Figures 4A and 7A), and the activities of E144Q and E144D mutants were reduced by 3000- and 10-fold, respectively (Figure 2A, lanes 18–20; Table 1). This strongly suggests that the negative charges on both E153 and E144 are critical for catalysis, while the length of the side chain (Glu vs. Asp) is also important.

We superimposed the active site residues of PRMT1 onto PRMT3, which was crystallized at pH ~6.3 [43] where PRMT3 has detectable activity (Figure 7C). As shown in Figure 7B, the largest deviation is between E153 and S154 of PRMT1 and the corresponding residues E335 and S336 of PRMT3. The superimposition placed the target arginine in between E326 and E335 of PRMT3; the side chain of E335 could form a bifurcated hydrogen bond with the guanidino group (Figure 7B). A network of charge-charge interactions involving E335, the target arginine, E326, R236, and the AdoHcy carboxylate would place the target nitrogen atom and the sulfur atom of AdoHcy into close proximity (shown by an arrow in Figure 7B). It has been proposed that the interaction with E335 of PRMT3 (equivalent to E153 of PRMT1) redistributes the positive charge on the guanidino group toward one amino group while leaving a lone pair of electrons on the other amino group to attack the cationic methylsulfonyl moiety of AdoMet [43]. The corresponding mutant of this residue in CARM1 (E267Q) has been used to demonstrate that the methyltransferase activity of CARM1 was required for synergy among nuclear receptor coactivators [48].

Biological Implications
We have described the crystal structures of the predominant protein arginine methyltransferase PRMT1, in the presence of methylation product AdoHcy and/or the peptide substrate containing either one or three target arginines. PRMT1 forms a ring-like dimer essential for AdoMet binding and enzymatic activity. The structure also reveals residues for catalysis (E153Q) and candidate residues for substrate recognition along three grooves (P1, P2, and P3). This structure provides useful starting points to map residues important for the binding of PRMT1 to its diverse protein substrates as well as other binding partners.

Experimental Procedures

Protein Expression and Purification
Rat PRMT1 gene was subcloned from the original GST-PRMT1 construct [17] by PCR into a modified pET28b (Novagen) vector, which adds a short N-terminal MGHHHHHH tag and accepts an Ndel-EcoRI insert. Deletions and point mutations were constructed by PCR using the same vector. Cultures of E. coli strain BL21(DE3) containing PRMT1 constructs were grown at 37°C to OD600 ~0.4, shifted to 22°C, and induced by 0.4 mM IPTG overnight at 22°C.

The His-tagged proteins were purified using Ni-chelating, Mono Q, and Sephacryl S300 columns (Amerham-Pharmacia). One hundred micromolar AdoHcy was incubated with the load samples of the Mono Q and S300 columns prior to chromatography. The proteins were homogeneous as judged by overloaded SDS-PAGE stained with Coomassie blue and their concentrations were estimated by OD280 absorption using a calculated extinction coefficient of 2.090 M−1 cm−1.

Nonagged proteins were expressed using vector pET29b (Novagen). The proteins were purified using two consecutive runs of Hitrap Q column, a Resource Q column, a 200HR Sephadex or S300 Sephacryl gel filtration column, followed by a Mono Q column (all Amerham-Pharmacia). During early steps of purification, PRMT activity using hnRNP A1 as substrate was determined. The full-length protein without tag and the S14 with His tag were both expressed poorly in E. coli (~20% of the others) for unknown reasons, although the majority of all expressed proteins was soluble. For comparison, the yield of full-length protein (plasmid pXC246) was about 0.4 mg/L with a final purity of about 80%, while the yield of the M11 deletion mutant (plasmid pXC247) was about 4 mg/L and >95% pure as judged by SDS-PAGE.

PRMT Activity Assay, UV Crosslinking, and Oligomerization
PRMT activity was assayed as described [43]. For UV crosslinking, 20 μl of PRMT1 (1–5 μg) was incubated with 0.5 μCi of [methyl-3H]AdoMet (78 Ci/mmol, NEN NET155H) overnight at 4°C. Samples were added to a 96-well plate and placed 8 cm from an upside-down UV transilluminator (VWR, 302 nm) for various times. The proteins were then separated by SDS-PAGE, stained with Coomassie blue, and subjected to fluorography.

The protein size (oligomerization) was determined by gel filtration chromatography on a Sephacryl S300 column using proteins (~0.5 mg/ml) preincubated with AdoHcy. The column buffer contained 20 mM Tris (pH 8.0), 250 mM NaCl, 1 mM EDTA, 0.1% 2-mercaptoethanol, and 5% glycerol. Size was estimated based on a standard run under the same buffer condition. The protein size was also determined by dynamic light scattering using DynaPro Molecular Sizing Instrument (Protein Solutions), at 1 mg/ml of protein concentration. The size shown in Table 1 was calculated with a regularization model.

Crystallography
The proteins were concentrated to about 20 mg/ml in the gel filtration column buffer with 600 μM of AdoHcy. Crystals were obtained via the hanging drop method, with the mother liquor containing 100
mM Tris (pH 9.0) and 1.6 M ammonium phosphate monobasic (final pH ~4.7). The concentration of peptide was 1 mM when present.

Complete data sets were collected at the beamlines X26C (wavelength 1.1 Å, ADSC Q4) and X12C (wavelength 1.1 Å, Brandeis B2) of the National Synchrotron Light Source, Brookhaven National Laboratory (Table 2). The structures were solved by molecular replacement using the refined PRMT3 core structure [45] as the search model, using AmoRe [49]; the resulting models were refined using X-PLOR [50]. Electron densities corresponding to the peptides were established in the difference Fourier annealed omit maps.

Acknowledgments

We thank Dr. Harvey R. Herschman (UCLA) for providing the construct to express the GST-PRMT1 fusion, Dr. Adrian Krainer (Cold Spring Harbor Laboratory) for providing the construct to express hnRNP A1, Susan Sunay for technical assistance during protein purification and crystallization, Paul Kearney for mutagenesis, Dr. Lan Zhou for help with X-ray data collection and molecular replacement, and Dr. Robert M. Blumenthal (Medical College of Ohio) for critical comments on the manuscript. These studies were supported in part by the National Institutes of Health (GM61355).

Received: November 20, 2002
Revised: February 13, 2003
Accepted: February 25, 2003
Published: May 6, 2003

References


Accession Numbers

The coordinates of the three PRMT1 structures have been deposited in the Protein Data Bank under ID codes 1ORI (pXC248), 1OR8 (pXC249), and 1ORH (pXC252), respectively.